Literature DB >> 27312983

Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials.

Joseph M Caster1, Artish N Patel1, Tian Zhang2, Andrew Wang1.   

Abstract

Nanomedicine is a relatively new field that is rapidly evolving. Formulation of drugs on the nanoscale imparts many physical and biological advantages. Such advantages can in turn translate into improved therapeutic efficacy and reduced toxicity. While approximately 50 nanotherapeutics have already entered clinical practice, a greater number of drugs are undergoing clinical investigation for a variety of indications. This review aims to examine all the nanoformulations that are currently undergoing clinical investigation and their outlook for ultimate clinical translation. WIREs Nanomed Nanobiotechnol 2017, 9:e1416. doi: 10.1002/wnan.1416 For further resources related to this article, please visit the WIREs website.
© 2016 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27312983     DOI： 10.1002/wnan.1416

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol        ISSN： 1939-0041


  66 in total

1.  Glucose-installed biodegradable polymeric micelles for cancer-targeted drug delivery system: synthesis, characterization and in vitro evaluation.

Authors:  Man Theerasilp; Punlop Chalermpanapun; Panya Sunintaboon; Witaya Sungkarat; Norased Nasongkla
Journal:  J Mater Sci Mater Med       Date:  2018-11-30       Impact factor: 3.896

Review 2.  Using Large Datasets to Understand Nanotechnology.

Authors:  Kalina Paunovska; David Loughrey; Cory D Sago; Robert Langer; James E Dahlman
Journal:  Adv Mater       Date:  2019-08-20       Impact factor: 30.849

Review 3.  Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.

Authors:  Humzah Jamshaid; Fakhar Ud Din; Gul Majid Khan
Journal:  J Nanobiotechnology       Date:  2021-04-15       Impact factor: 10.435

4.  Self-assembly of four generations of RNA dendrimers for drug shielding with controllable layer-by-layer release.

Authors:  Xin Li; Mario Vieweger; Peixuan Guo
Journal:  Nanoscale       Date:  2020-07-30       Impact factor: 7.790

Review 5.  Nucleic acid nanomedicines in Phase II/III clinical trials: translation of nucleic acid therapies for reprogramming cells.

Authors:  Victoria Lm Herrera; Aaron H Colby; Nelson Ruiz-Opazo; David G Coleman; Mark W Grinstaff
Journal:  Nanomedicine (Lond)       Date:  2018-09-11       Impact factor: 5.307

Review 6.  Advances in the clinical translation of nanotechnology.

Authors:  David A Scheinberg; Jan Grimm; Daniel A Heller; Evan P Stater; Michelle Bradbury; Michael R McDevitt
Journal:  Curr Opin Biotechnol       Date:  2017-02-07       Impact factor: 9.740

Review 7.  Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines.

Authors:  Geoffrey M Lynn; Richard Laga; Christopher M Jewell
Journal:  Cancer Lett       Date:  2019-06-08       Impact factor: 8.679

8.  Progress in Nanomedicine: Approved and Investigational Nanodrugs.

Authors:  C Lee Ventola
Journal:  P T       Date:  2017-12

9.  Functional muscle recovery with nanoparticle-directed M2 macrophage polarization in mice.

Authors:  Theresa M Raimondo; David J Mooney
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-01       Impact factor: 11.205

Review 10.  Pharmacokinetics of nanotechnology-based formulations in pediatric populations.

Authors:  Venkata K Yellepeddi; Andrea Joseph; Elizabeth Nance
Journal:  Adv Drug Deliv Rev       Date:  2019-09-05       Impact factor: 15.470
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.